– EYP-1901 combines vorolanib with EyePoint’s bioerodible Durasert™ technology as a six-month sustained release intravitreal therapeutic program to potentially reduce […]
VANCOUVER, Colúmbia Britânica, Feb. 03, 2020 (GLOBE NEWSWIRE) — EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2) (a “Empresa” ou “EXM“), um produtor de [...]